Levetiracetam Tablet, Film Coated
Product Images NDC 68084-882

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68084-882). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp85901

Levetiracetam 750 mg film-coated oral tablet, imprint E 10 on one side, smooth and oval in shape, pale blue in color. Manufacturer: American Health Packaging.*

FDA Label Image

Ahp88201

Levetiracetam 250 mg film-coated oral tablet imprinted with "E 12" on one side and plain on the other, provided by American Health Packaging.*

FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical structure diagram of levetiracetam, showing the molecular framework including a pyrrolidone ring and associated functional groups.*

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

A bar graph titled "Responder Rate (≥50% Reduction from Baseline) in Study 1" showing the percentage of patients achieving at least 50% reduction. It compares placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day groups. The placebo group has a 7.4% responder rate, Levetiracetam 1000 mg/day has 37.1%, and Levetiracetam 3000 mg/day has 39.6%, with both Levetiracetam groups marked statistically significant versus placebo.*

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing the percentage of patients achieving this response. The graph compares placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Statistically significant differences versus placebo are indicated for both Levetiracetam doses.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' showing percentage of patients achieving at least 50% reduction. The chart compares Placebo (104 patients) with a 14.4% responder rate to Levetiracetam 3000 mg/day (180 patients) with a 39.4% responder rate, marked statistically significant versus placebo.*

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

A bar chart labeled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing percentage of patients responding to Placebo (19.6%) and Levetiracetam (44.6%) treatments. The chart shows higher responder rate for Levetiracetam with statistical significance indicated versus placebo.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

A bar chart titled 'Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5' comparing the percentage of patients for placebo and Levetiracetam groups. The placebo group (N=51) shows a responder rate of 19.6%, while the Levetiracetam group (N=58) shows a higher responder rate of 43.1%, marked as statistically significant versus placebo.*

FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' comparing Placebo and Levetiracetam groups. The vertical axis shows the percentage of patients, with Placebo at 45.2% and Levetiracetam at 72.2%, indicating a statistically significant difference in responder rates favoring Levetiracetam.*

FDA Label Image

250 mg Levetiracetam Tablets Carton.jpg (250 mg Levetiracetam Tablets Carton)

Levetiracetam 250 mg film-coated tablets label from American Health Packaging. The label indicates a package of 100 tablets (10 blister cards of 10 each). It includes storage instructions, dosing advice to see full prescribing information, and a barcode with NDC 68084-859-01. A QR code is present for accessing the Medication Guide and prescribing information.*

FDA Label Image

250 mg Levetiracetam Tablet Blister (Image 02)

Multiple film-coated tablet labels for Levetiracetam 250 mg by American Health Packaging. Each label includes the drug name, strength, barcode, placeholders for expiration date and lot number, and the labeler's location in Columbus, Ohio.*

FDA Label Image

750 mg Levetiracetam Tablets Carton.jpg (750 mg Levetiracetam Tablets Carton)

Levetiracetam 750 mg film-coated oral tablets label showing packaging for 100 tablets (10 x 10), Rx Only. The label includes the National Drug Code (NDC) 68084-882-01, barcode, medication guide dispensing instructions, storage temperature guidelines (20° to 25°C with excursions), and a QR code for current medication guide and prescribing information. Distributed by American Health Packaging, Columbus, Ohio.*

FDA Label Image

750 mg Levetiracetam Tablet Blister (Image 06)

Levetiracetam 750 mg film-coated tablets labeling from American Health Packaging. The label includes the proprietary and generic name Levetiracetam, strength of 750 mg, route of oral administration, and a barcode. Expiration date and lot number fields are present but not filled in. The labeling is repeated multiple times on the sheet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.